Study of BL-M07D1 for ovarian cancer that has returned after platinum treatment
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial compares an investigational drug called BL-M07D1 with standard chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has come back despite previous platinum-based treatment. The goal is to see if BL-M07D1 is more effective than the doctor's choice of chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have ovarian, fallopian tube, or primary peritoneal cancer that is confirmed to be platinum-resistant (came back within 6 months of completing platinum chemotherapy).
- You must have received 1 to 3 prior lines of cancer therapy.
- You must have at least one measurable tumor (as per standard criteria).
- You must be in generally good health (able to do light activities, as per standard assessment).
- If you have previously tested positive for a marker called FRα, you must have received a specific drug called mirvetuximab soravtansine (if that was part of your treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
This trial tests a new drug called BL-M07D1 for women with HER2-positive or low-HER2 gynecologic cancers that have returned or spread. The drug is designed to target and kill cancer cells that make HER2, and may help when other treatments have stopped working.
This study tests a new drug called BL-M05D1 for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called BL-M07D1 for people with certain advanced solid tumors that have the HER2 protein (high or low amounts). The goal is to see if it can shrink or slow the growth of these cancers, especially in urinary and digestive system tumors.
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
This trial tests a new drug called BL-M07D1 against standard chemotherapy for biliary tract cancer that has spread or is locally advanced and has stopped responding to platinum-based chemotherapy. The trial is looking for patients whose cancer has a specific genetic marker to see if this new treatment works better.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.